Table 2. Comparisons of demographics, past medical history, clinical manifestation and vasoconstriction severity of reversible cerebral vasoconstriction syndromes in association with brain-derived neurotrophic factor Val66Met polymorphisms.
| Val/Val(n = 19) | Val/Met(n = 45) | Met/Met(n = 26) | P† | |
| Age (y), mean ± SD | 48.9±11.0 | 48.0±9.5 | 47.7±11.7 | 0.924 |
| Gender, M/F | 4/15 | 3/42 | 4/22 | 0.238 |
| Hypertension, n (%) | 2 (10.5) | 8 (17.8) | 7 (26.9) | 0.376 |
| Type 2 DM, n (%) | 1 (5.3) | 2 (4.4) | 1(7.7) | 0.850 |
| Migraine, n (%) | 3 (15.8) | 10 (22.2) | 5 (19.2) | 0.840 |
| BP surge, n (%) | 7 (36.8) | 22 (48.9) | 10 (38.4) | 0.574 |
| Total TCH attacks, mean ± SD | 9.9±10.9 | 6.2±4.2 | 5.2±3.4 | 0.097 |
| TCH duration (d), mean ± SD | 17.5±10.3 | 16.6±11.1 | 16.7±13.4 | 0.970 |
| Mean vasoconstriction score, mean ± SD | ||||
| M1 | 1.24±1.02* | 1.78±1.03* | 0.58±0.52 | <0.001 |
| M2 | 1.53±1.42 | 2.17±1.04** | 1.12±0.90 | 0.001 |
| A1 | 2.00±1.13** | 1.95±0.97** | 0.90±0.60 | <0.001 |
| A2 | 1.34±0.97 | 1.47±0.91 | 0.96±0.69 | 0.064 |
| P1 | 1.39±0.95 | 1.37±1.04 | 0.83±0.78 | 0.057 |
| P2 | 2.03±1.09* | 1.92±0.92* | 1.19±0.98 | 0.005 |
| BA | 0.63±0.90 | 0.70±0.93 | 0.31±0.62 | 0.160 |
| All segments | 1.43±0.73* | 1.70±0.70* | 0.87±0.39 | <0.001 |
| VMCA | 111.1±33.3* | 113.4±38.0** | 82.7±17.9 | 0.003 |
| LI | 2.32±0.79 | 2.45±0.97 | 1.89±0.41 | 0.050 |
| PRES, n (%) | 0 (0) | 4 (9) | 1 (4) | 0.338 |
| Ischemic stroke, n (%) | 0 (0) | 3 (7) | 2 (8) | 0.493 |
BA: basilar artery, BP: blood pressure, DM: diabetes mellitus, LI: Lindegaard index, PRES: posterior reversible encephalopathy syndrome, TCH: thunderclap headache, VMCA: mean flow velocity of the middle cerebral artery.
†
Derived by analysis of variance (ANOVA) test.
*p<0.05 & **p<0.01 in comparison with Met/Met homozygotes using post-hoc Scheffe test.